Trials / Terminated
TerminatedNCT02137096
Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
High Dose Conditioning With Ifosfamide, Carboplatin, and Etoposide With Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- University of Florida · Academic / Other
- Sex
- All
- Age
- 2 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
This is a pilot study to evaluate the response rates for patients undergoing high dose conditioning chemotherapy using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent Nasopharyngeal Cancer (NPC) in children, adolescents, and young adults.
Detailed description
The use of high dose chemotherapy followed by autologous peripheral blood stem cell (PBSC) transplantation in recurrent nasopharyngeal carcinoma has shown promise when compared with standard chemotherapy. This study has been designed to evaluate response rates and toxicities associated with undergoing high dose conditioning with Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation support in the treatment of recurrent nasopharyngeal carcinoma in children, adolescents, and young adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etoposide phosphate | Etoposide is one of three drugs used in the high-dose conditioning phase |
| DRUG | Carboplatin | Carboplatin is one of the drugs used in the high-dose conditioning phase. |
| DRUG | Ifosfamide | Ifosfamide is one of the drugs used in the high-dose conditioning phase |
| PROCEDURE | Autologous Stem Cell Transplantation | Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm. |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2017-05-09
- Completion
- 2017-05-09
- First posted
- 2014-05-13
- Last updated
- 2019-06-24
- Results posted
- 2019-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02137096. Inclusion in this directory is not an endorsement.